Background: The aim of this study is to evaluate the efficacy and safety of tadalafil, a phosphodiesterase type 5 inhibitor, plus mirabegron, a β3-adrenoreceptor agonist, in patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment. Methods: The registration of this study started in August 2016 and ended in July 2019. The inclusion criteria included patients aged ? 50 years who were diagnosed with benign prostatic hyperplasia and who presented with overactive bladder symptoms. Patients were treated with oral tadalafil 5 mg once daily for 4 weeks. Then, its efficacy was evaluated. Patients who responded to the treatment received oral tadalafil 5 mg once daily for 4 more weeks (mon...
Background: To evaluate the efficacy and safety profile of alpha-1A receptor subtype specific antago...
Lower urinary tract symptoms (LUTS) secondary to benign prostrate hyperplasia (BPH) are common geria...
Background: Tadalafil improved lower urinary tract symptoms (LUTS) suggestive of benign prostatic hy...
Background: Tadalafil has been approved for the treatment of benign prostatic hyperplasia (BPH) for ...
Benign prostatic hyperplasia (BPH) is an age-related phenomenon associated with prostatic enlargemen...
Background: Benign prostate hyperplasia (BPH) is the most common pathological condition that contrib...
Background: Tadalafil is being investigated for the treatment of lower urinary tract symptoms (LUTS)...
OBJECTIVES: To evaluate safety and efficacy of tadalafil on lower urinary tract symptoms (LUTS) sugg...
Introduction: Benign prostatic hyperplasia (BPH) is highly prevalent in elderly men and often result...
Introduction: Due to aging of the general population, prevalence of Benign Prostatic Enlargement is ...
This prospective study evaluated the safety of tadalafil 5 mg taken once a day in terms of hypotensi...
Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a ...
Title: Survey the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in...
Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a ...
Introduction: Tadalafil and Tamsulosin have both been approved for use in the management of lower ur...
Background: To evaluate the efficacy and safety profile of alpha-1A receptor subtype specific antago...
Lower urinary tract symptoms (LUTS) secondary to benign prostrate hyperplasia (BPH) are common geria...
Background: Tadalafil improved lower urinary tract symptoms (LUTS) suggestive of benign prostatic hy...
Background: Tadalafil has been approved for the treatment of benign prostatic hyperplasia (BPH) for ...
Benign prostatic hyperplasia (BPH) is an age-related phenomenon associated with prostatic enlargemen...
Background: Benign prostate hyperplasia (BPH) is the most common pathological condition that contrib...
Background: Tadalafil is being investigated for the treatment of lower urinary tract symptoms (LUTS)...
OBJECTIVES: To evaluate safety and efficacy of tadalafil on lower urinary tract symptoms (LUTS) sugg...
Introduction: Benign prostatic hyperplasia (BPH) is highly prevalent in elderly men and often result...
Introduction: Due to aging of the general population, prevalence of Benign Prostatic Enlargement is ...
This prospective study evaluated the safety of tadalafil 5 mg taken once a day in terms of hypotensi...
Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a ...
Title: Survey the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in...
Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a ...
Introduction: Tadalafil and Tamsulosin have both been approved for use in the management of lower ur...
Background: To evaluate the efficacy and safety profile of alpha-1A receptor subtype specific antago...
Lower urinary tract symptoms (LUTS) secondary to benign prostrate hyperplasia (BPH) are common geria...
Background: Tadalafil improved lower urinary tract symptoms (LUTS) suggestive of benign prostatic hy...